Replies to post #228801 on Biotech Values

[Bickema]

RVNC - hard to pinpoint the weakness in today's price action with the entire market sell off.

But a few things of note was RVNC won't be reporting any meaningful revenue wrt to the Teoxane fillers until the end of the year due to sampling.

Also the cash burn for 2020 looks pretty high at: 2020 GAAP operating expense to be in the range of $272 million to $280 million and non-GAAP operating expense, which excludes depreciation and stock-based compensation, in the range of $222 million to $230 million.

Then's there's always the chance that algo's are selling off the "RVNC misses by .05" headline which is common in non revenue producing bios.

[DewDiligence]

RVNC 1Q20 results—3/31/20 cash=$511M:

https://investors.revance.com/news-releases/news-release-details/revance-reports-first-quarter-2020-financial-results-provides

2020 operating cash burn is expected to be at the low end of the prior guidance range of $220-230M due to one-quarter delay (to 3Q20) in the US launch of Teoxane’s dermal fillers.

MYL’s decision whether to opt in for the Botox-biosimilar program is expected by the end of May.